O'Callaghan Chris A
Henry Wellcome Building for Molecular Physiology, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Curr Opin Pharmacol. 2009 Apr;9(2):90-5. doi: 10.1016/j.coph.2008.11.001. Epub 2008 Dec 16.
CLEC-2 is a C-type lectin-like molecule that has recently been identified as a receptor on the surface of platelets. Ligand binding by CLEC-2 promotes phosphorylation of a tyrosine in the cytoplasmic domain YXXL motif of CLEC-2 by Src kinases and further downstream signalling events trigger platelet activation and aggregation. The snake venom protein rhodocytin and the endogenous protein podoplanin have been identified as ligands. The structures of CLEC-2 and rhodocytin suggest that ligand binding could cluster CLEC-2 molecules at the platelet surface, so initiating signalling. CLEC-2 is a promising target for therapeutic strategies to inhibit platelet activity in thrombotic vascular disease.
C型凝集素样受体-2（CLEC-2）是一种C型凝集素样分子，最近被鉴定为血小板表面的一种受体。CLEC-2与配体结合可促进Src激酶对CLEC-2胞质结构域YXXL基序中酪氨酸的磷酸化，进一步的下游信号事件可触发血小板活化和聚集。蛇毒蛋白红树毒素和内源性蛋白血小板反应蛋白-1已被鉴定为配体。CLEC-2和红树毒素的结构表明，配体结合可使CLEC-2分子在血小板表面聚集，从而启动信号传导。CLEC-2是血栓性血管疾病中抑制血小板活性治疗策略的一个有前景的靶点。
